

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-23. Cancel

24. (New) An isolated human IL-2 mutein having a substitution at position 20 relative to wild type IL-2 (Seq. ID No. 1) wherein said substitution is with an amino acid selected from the group consisting of isoleucine, histidine, tyrosine, and methionine, whereby said mutein preferentially activates T cells over Natural Killer cells.

25. (New) The IL-2 mutein of Claim 24, wherein said position 20 is substituted with isoleucine.

26. (New) The IL-2 mutein of Claim 24, wherein said position 20 is substituted with histidine.

27. (New) The IL-2 mutein of Claim 24, wherein said position 20 is substituted with tyrosine.

28. (New) The IL-2 mutein of Claim 24, wherein said position 20 is substituted with methionine.

29. (New) A polynucleotide comprising a DNA sequence that encodes the human IL-2 mutein of Claim 24.

30. (New) A vector comprising the polynucleotide of Claim 29.

31. (New) A prokaryotic host cell transformed with the polynucleotide of Claim 29.

32. (New) An eukaryotic host cell transformed with the polynucleotide of Claim 29.

33. (New) A pharmaceutical composition comprising a human IL-2 mutein of Claim 24 in combination with a pharmaceutically acceptable carrier.